tirzepatide 10mg pen Mounjaro 10 mg/0.5 mL pre-filled single-dose Images MOUNJARO® Prefilled Pen (Tirzepatide)* Inj

All of these treatments have the potential to positively affect folate, methylation and glutathione pathways

You have a BMI of 27+ with a weight-related health concern You've tried diet and exercise without achieving lasting results You struggle with food cravings or feeling hungry even after meals You have insulin resistance, PCOS, or hormonal imbalances You've experienced weight regain after previous weight loss You want a medically supervised, sustainable approach What to expect realistic results Semaglutide: average 1315% body weight loss in clinical trials Tirzepatide: average 2022% body weight loss in clinical trials Most patients notice reduced appetite within the first 24 weeks With protein guidance and exercise, most patients preserve muscle Full results develop over 612 months of consistent treatment Results vary by individual

Official communication about our medicines containing semaglutide from Novo Nordisk This site is intended for a US audience Latest on compounded and counterfeit products and other important information about semaglutide Latest on compounded and counterfeit products and other semaglutide information Patient safety is our top priority, and we are concerned about unapproved compounded semaglutide exposing patients to serious safety and efficacy risks

Always adhere to your providers recommended schedule for follow-up visits to ensure you receive optimal care throughout your treatment with Tirzepatide